April 23, 2025 Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
April 3, 2025 Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
March 26, 2025 Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD
October 22, 2024 Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT
June 7, 2024 Epicrispr Biotechnologies to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress
May 23, 2024 Epicrispr Biotechnologies to Participate in Fireside Chat at Stifel’s Genetic Medicines Forum
April 23, 2024 Epicrispr Biotechnologies Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting
April 10, 2024 Epicrispr Biotechnologies to Participate in a Fireside Chat Titled Genetic Medicine for Generalists Hosted by Canaccord
April 9, 2024 Epicrispr Biotechnologies Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
April 1, 2024 Epicrispr Biotechnologies to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium
March 13, 2024 Epicrispr Biotechnologies to Present at the Upcoming Charles River Cell and Gene Therapy Summit
